HUTCHMED (China) Limited (HCM:NASDAQ) closed at $14.36 on October 23, 2026, up 0.56% on the day. The stock trades 12.1% below its 52-week high of $16.33 and 47.0% above its 52-week low of $9.77. Over the past year, it lost 2.7%. HUTCHMED (China) Limited is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, HCM closed higher on 129 days (51%). Its best day was September 3, 2026 (+17.19%) and its worst was July 17, 2026 (-6.63%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides drug research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and health-related consumer products under the Bai Yun Shan and Shang Yao brands. It also develops clinical drug candidates, including AZD6094 that is in Phase Ib clinical trial for treating non-small cell lung and gastric cancer; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib, a Phase Ib clinical trial product for neuroendocrine tumors and thyroid cancers; and HMPL-523, a preclinical stage product for the treatment of immunology, rheumatoid arthritis, lupus, and hematological cancers. In addition, the company is developing Epitinib for the treatment of non-small cell lung cancer; Theliatinib, a Phase I clinical trial product for the treatment of solid tu...
Find more stocks like HCM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.